HK116494A - Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones - Google Patents

Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones Download PDF

Info

Publication number
HK116494A
HK116494A HK116494A HK116494A HK116494A HK 116494 A HK116494 A HK 116494A HK 116494 A HK116494 A HK 116494A HK 116494 A HK116494 A HK 116494A HK 116494 A HK116494 A HK 116494A
Authority
HK
Hong Kong
Prior art keywords
aza
androst
methyl
hydrogen
carbamoyl
Prior art date
Application number
HK116494A
Other languages
English (en)
French (fr)
Inventor
H. Rasmusson Gary
F. Reynolds Glen
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21878727&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK116494(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of HK116494A publication Critical patent/HK116494A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/16—Benz[e]indenes; Hydrogenated benz[e]indenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Claims (8)

  1. Verwendung einer Verbindung der Formel in der R¹ Wasserstoff, Methyl oder Ethyl, R² verzweigtkettiges Alkyl mit 3-12 Kohlenstoffatomen, R' Wasserstoff oder Methyl, R'' Wasserstoff oder β-Methyl, R''' Wasserstoff, α-Methyl oder β-Methyl bedeuten, zur Herstellung eines Arzneimittels, das zur Behandlung der androgenen Alopezie verwendbar ist.
  2. Verwendung gemäß Anspruch 1, worin R¹ Wasserstoff oder Methyl, R² verzweigtkettiges Alkyl mit 4-8 Kohlenstoffatomen und R', R'' und R''' Wasserstoff bedeuten.
  3. Verwendung gemäß Anspruch 1, worin die Verbindungen    17β-(N-tert.Butylcarbamoyl)-4-aza-4-methyl-5α-androst-1-en-3-on,    17β-(N-tert.Butylcarbamoyl)-4-aza-5α-androst-1-en-3-on,    17β-(N-Isobutylcarbamoyl)-4-aza-4-methyl-5α-androst-1-en-3-on,    17β- (N-Isobutylcarbamoyl)-4-aza-5α-androst-1-en-3-on,    17β-(N-tert.Octylcarbamoyl)-4-aza-4-methyl-5α-androst-1-en-3-on,    17β-(N-tert.Octylcarbamoyl)-4-aza-5α-androst-1-en-3-on,    17β-(N-1,1-Diethylbutylcarbamoyl)-4-aza-4-methyl-5α-androst-1-en-3-on,    17β-(N-1,1-Diethylbutylcarbamoyl)-4-aza-5α-androst-1-en-3-on,    17β-(N-tert.Hexylcarbamoyl)-4-aza-4-methyl-5α-androst-1-en-3-on oder    17β-(N-tert.Hexylcarbamoyl)-4-aza-5α-androst-1-en-3-on sind.
  4. Verwendung gemäß Anspruch 3, worin die Verbindung 17β-(N-tert.Butylcarbamoyl)-4-aza-5α-androst-1-en-3-on ist.
  5. Verwendung von 17β-(N-tert.Butylcarbamoyl)-4-aza-5α-androst-1-en-3-on zur Herstellung eines Arzneimittels, das für die Hemmung der androgenen Alopezie und deren Rückwandlung brauchbar ist.
  6. Verwendung gemäß jedem der vorhergehenden Ansprüche, worin die androgene Alopezie eine Alopezie der männlichen Form ist.
  7. Verwendung gemäß jedem der vorhergehenden Ansprüche, worin das hergestellte Arzneimittel etwa 0,1% bis 15% der Verbindung und einen pharmazeutisch annehmbaren Träger enthält.
  8. Verwendung gemäß jedem der vorhergehenden Ansprüche, worin das hergestellte Arzneimittel eine Lösung, eine Creme, eine Salbe, ein Gel, ein Shampoo oder ein Aerosol ist.
HK116494A 1987-04-03 1994-10-27 Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones HK116494A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3480687A 1987-04-03 1987-04-03

Publications (1)

Publication Number Publication Date
HK116494A true HK116494A (en) 1994-11-04

Family

ID=21878727

Family Applications (1)

Application Number Title Priority Date Filing Date
HK116494A HK116494A (en) 1987-04-03 1994-10-27 Treatment of androgenic alopecia with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones

Country Status (5)

Country Link
EP (1) EP0285382B1 (de)
CA (1) CA1302277C (de)
CY (1) CY1807A (de)
DE (1) DE3888994T2 (de)
HK (1) HK116494A (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2085605C (en) * 1990-08-10 2003-03-11 Arthur Robert Diani Stimulation of hair growth with potassium channel openers and 5alpha-reductase inhibitors
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
GB2274060A (en) * 1993-01-07 1994-07-13 Merck & Co Inc Treatment of patterned alopecia with 17ß-acyl-4-aza-5-androst-1-ene-3-ones and minoxidil
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids
WO1994022900A1 (en) * 1993-04-02 1994-10-13 Ciba-Geigy Ag AZA-ANDROSTANE-17β-CARBOXAMIDES
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
RU2173152C2 (ru) * 1993-10-15 2001-09-10 Мерк Энд Ко., Инк. Способ лечения андрогенной алопеции ингибиторами 5-альфа-редуктазы
TW382595B (en) * 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US5547957A (en) * 1993-10-15 1996-08-20 Merck & Co., Inc. Method of treating androgenic alopecia with 5-α reductase inhibitors
AU700565B2 (en) * 1993-10-15 1999-01-07 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitor formulations
HUT74613A (en) * 1993-10-21 1997-01-28 Merck & Co Inc 16-substituted-4-aza-androstane derivatives as 5-alpha-reductase isozyme 1 inhibitors and pharmaceutical compositions containing the same
US5541322A (en) * 1994-10-14 1996-07-30 Glaxo Wellcome Inc. Synthesis of 6-azaandrostenones
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
AU7078296A (en) * 1995-09-27 1997-04-17 Merck & Co., Inc. Method of preventing androgenetic alopecia with 5-alpha reductase inhibitors
IL124764A0 (en) * 1998-06-04 1999-01-26 Univ Ben Gurion Topical composition for treatment of baldness
DE60313603T2 (de) 2002-04-24 2008-01-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische kombination zur behandlung von benigner prostatahyperplasie oder zur langzeitvorbeugung von akuter harnzurückhaltung
SI1644024T1 (sl) 2003-06-06 2019-11-29 Univ Texas Protimikrobne raztopine za izpiranje
LT2344198T (lt) 2008-09-27 2021-02-25 Jina Pharmaceuticals Inc. Farmaciniai preparatai lipidų pagrindu, skirti vietiniam naudojimui

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU527030B2 (en) * 1978-04-13 1983-02-10 Merck & Co., Inc. 4-aza-17-substituted-5a-androstan-3-ones
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
DE3888994D1 (de) 1994-05-19
EP0285382B1 (de) 1994-04-13
CA1302277C (en) 1992-06-02
EP0285382A3 (en) 1990-09-12
CY1807A (en) 1995-09-08
EP0285382A2 (de) 1988-10-05
DE3888994T2 (de) 1994-11-03

Similar Documents

Publication Publication Date Title
EP0285383B1 (de) Behandlung von Prostatacarcinoma mit 17-beta-n-monosubstituierten-Carbamoyl-4-aza-5-alpha-Androst-1-en-3-onen
US4760071A (en) 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
EP0155096B1 (de) 17 Beta-substituierte-4-aza-5-alpha-Androstenone und ihre Anwendung als 5-alpha-Reduktase-Inhibitoren
US4377584A (en) 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
EP0285382B1 (de) Behandlung von androgener Alopecia mit 17-bêta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen
US4845104A (en) Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
EP0314199B1 (de) 17-Beta-substituierte-4-aza-5-alpha-Androstenone und ihre Anwendung als 5-Alpha-Reduktase-Inhibitoren
EP0414491A2 (de) 17-Beta-acyl-4-aza-5-alpha-androst-1-en-one als Inhibitoren der 5-alpha-Reduktase
US5567708A (en) Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones]
EP0271219A1 (de) Topisches Arzneimittel enthaltend 17-beta-Methoxy-carbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one
EP0414490A2 (de) 17-Beta-acyl-4-aza-5-alpha-androst-1-en-3one als Inhibitoren der 5-alpha-Reduktase
US5061802A (en) 17β-aminobenzoyl-4-aza-5α-androst-1-en-3-ones as benign prostatic hypertrophy agents
EP0547691B1 (de) Verwendung von 17B-N-Mono-substituierten Carbamoyl-4-aza-5a-androst-1-en-3-onen zur Herstellung von Arzneimitteln zur Verhütung von Prostata Karzinomen
AU691164B2 (en) Method of treatment of chronic prostatitis with 17beta -N-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-E N-3-ones
US5162332A (en) Selected 17 β-polyaroyl-4-aza-5 α-androst-1-en-3-ones as steroidal reductase inhibitors
EP0462665A2 (de) 17-Beta-polyaroyl-4-aza-5-alpha-androst-1-en-3-one, als Inhibitoren der Steroidreduktasen
EP0547687A1 (de) 17-Beta-substituierte Adamantyl/Norbornanyl Carbamoyl-4-Aza-5-Alpha-Androsta-1-En-3-Onen und Androstan-3-Onen
JPS60222497A (ja) ５αリダクターゼの阻害剤としての１７β―Ｎ―モノ置換カルバモイル―４―アザ―５α―アンドロスタ―１―エン―３―オン類
BG61203B2 (bg) 17 бета-n-моносубституирани карбамоил-4-аза-5-андрост- 1-ен-3-они действуващи като инхибитори на тестостерон 5 алфа-редуктазата
EP0547690A1 (de) Verwendung von 17B-Acyl-4-aza-5a-androst-1-en-3-onen zur Herstellung von Medikamenten zur Verhütung von Prostata Karzinomen

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080329